Skip to main content
Figure 4 | BMC Neurology

Figure 4

From: Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial

Figure 4

Change in 36-item Short-Form Health Survey Mental Component Summary scores. The figure shows the LSM change from baseline to 6 months ± standard error. GA, glatiramer acetate; iDMT, injectable disease-modifying therapy; IFN, interferon; IM, intramuscular; LSM, least-squares mean; SC, subcutaneous.

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us